非HIV感染儿童肺孢子菌肺炎临床特征分析
单中心回顾性分析四川大学华西第二医院儿科2022年2月至2025年6月收治的59例非HIV感染肺孢子菌肺炎患儿,就诊年龄0.5(0.3,2.5)岁,51%诊断前有糖皮质激素及免疫抑制剂使用史,97%存在混合感染,mNGS均检出肺孢子菌,93%好转、7%死亡;合并基础疾病组与无基础疾病组住院时间、ICU入住率及时间、机械通气率、病死率差异均无统计学意义(均P>0.05)。
要点
- 非HIV感染儿童PJP好发于3岁以下婴幼儿,多合并免疫缺陷等基础疾病及激素/免疫抑制剂使用史。
- 临床表现与影像学缺乏特异性,mNGS有助于早期诊断,97%存在混合感染。
- 治疗以复方磺胺甲噁唑为核心,多需呼吸支持,联用小剂量糖皮质激素可能改善预后。
核心结论
- 非HIV感染儿童PJP好发于3岁以下婴幼儿,常合并免疫缺陷等基础疾病,多有激素、免疫抑制剂使用史。
- 临床表现和影像学缺乏特异性,mNGS有助于早期诊断。
- 治疗以复方磺胺甲噁唑为核心,多需呼吸支持,联用小剂量糖皮质激素可能改善预后。
研究设计与样本
- 单中心回顾性病例系列研究,分析四川大学华西第二医院儿科2022年2月至2025年6月收治的59例非HIV感染PJP患儿。
- 根据是否合并基础疾病分为有基础疾病组(36例)和无基础疾病组(23例),组间比较采用Mann-Whitney U检验、χ²检验或Fisher确切概率法。
主要发现
- 59例患儿就诊年龄0.5(0.3,2.5)岁,男40例、女19例;原发性免疫缺陷病12例(20%),自身免疫性疾病、血液肿瘤及器官移植各4例(11%),30例(51%)诊断前有糖皮质激素及免疫抑制剂治疗史。
- 主要症状为咳嗽57例(97%)、呼吸困难51例(86%)、发热35例(59%);外周血白细胞计数9.2(6.3,13.9)×10⁹/L,中性粒细胞4.4(1.8,7.4)×10⁹/L,淋巴细胞3.4(2.0,6.1)×10⁹/L,CRP 1.4(0.5,11.6)mg/L,降钙素原0.2(0.1,0.6)μg/L,乳酸脱氢酶(582±49)U/L。
- 53%(16/30)真菌G试验阳性;27%(11/41)CD4⁺T细胞数<0.5×10⁹/L,32%(13/41)CD4⁺/CD8⁺<1.0。
- 影像学表现双肺多发实变影或片状影48例(81%)、弥漫性磨玻璃影29例(49%)、透光性降低20例(34%);所有患儿均经mNGS发现肺孢子菌,57例(97%)存在混合感染。
- 复方磺胺甲噁唑单药治疗34例(58%),联用米卡芬净19例(32%),联用克林霉素7例(12%);53例(90%)需要呼吸支持,41例(70%)开始针对性治疗时予以糖皮质激素;55例(93%)好转,4例(7%)死亡。
关键数值与推荐
- 有基础疾病组36例与无基础疾病组23例比较,住院时间、ICU入住率及入住时间、机械通气率、病死率差异均无统计学意义(均P>0.05)。
临床怎么用
- 对3岁以下婴幼儿,尤其有免疫缺陷等基础疾病或激素、免疫抑制剂使用史者,出现咳嗽、呼吸困难、发热时应警惕PJP。
- 临床与影像学缺乏特异性时,可借助mNGS早期检出肺孢子菌,并注意97%存在混合感染。
- 治疗以复方磺胺甲噁唑为核心,多数患儿需呼吸支持,开始针对性治疗时联用小剂量糖皮质激素可能改善预后。
局限性
- 单中心回顾性病例系列研究,样本量59例。
- 原文未报告随访时间及长期预后信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To analyze the clinical characteristics of Pneumocystis jirovecii pneumonia (PJP) in non-human immunodeficiency virus (HIV) infected children, aiming to provide a basis for early diagnosis, timely treatment, and improved prognosis. Methods: A single-center retrospective case series study was conducted to analyze the general information, laboratory indicators, imaging features, treatment, and outcomes of 59 pediatric patients with non-HIV-infected PJP admitted to the Department of Pediatrics, West China Second Hospital, Sichuan University, from February 2022 to June 2025.These patients were categorized into two groups based on the presence or absence of underlying diseases.Comparative analysis was performed to assess differences in hospitalization duration, intensive care unit (ICU) admission rate, mechanical ventilation rate, mortality, and other relevant aspects between the 2 groups.The rank sum test, χ² test or Fisher exact test was employed for intergroup comparisons. Results: The age at presentation of 59 patients: 0.5 (0.3, 2.5) years, including 40 males and 19 females. Among the underlying diseases, there were 12 cases (20%) of primary immunodeficiency, 4 cases (11%) each of autoimmune diseases, hematologic malignancies, and organ transplantation 30 cases (51%) had received treatment with glucocorticoids and immunosuppressants before diagnosis. The main clinical symptoms were cough in 57 cases (97%), dyspnea in 51 cases (86%) and, fever in 35 cases (59%). The peripheral white blood cell count was 9.2 (6.3, 13.9)×109/L, with neutrophils 4.4 (1.8, 7.4)×109/L and lymphocytes 3.4 (2.0, 6.1)×109/L. C-reactive protein (CRP) 1.4 (0.5, 11.6) mg/L, procalcitonin 0.2 (0.1, 0.6) μg/L, the lactate dehydrogenase was (582±49) U/L. Fifty-three percent (16/30) of fungal G-test results were positive, 27% (11/41) of the children had CD4+ T-cell counts <0.5×109/L, and 32% (13/41) had CD4+/CD8+ ratios <1.0.The main imaging findings included consolidation or patchy opacities in 48 cases (81%), diffuse ground-glass opacities in 29 cases (49%), and decreased transparency in 20 cases (34%). Pneumocystis was detected via metagenomic next-generation sequencing (mNGS) in all cases. Co-infections were present in 57 cases (97%). Among the 59 pediatric patients, 34 cases (58%) were treated with trimethoprim-sulfamethoxazole monotherapy, 19 cases (32%) received combination therapy with micafungin, and 7 cases (12%) received combination therapy with clindamycin. Fifty-three cases (90%) required varying degrees of respiratory support. Concurrent glucocorticoid therapy was administered in 70% (41/59) of cases at anti-PJP treatment initiation. Fifty-five cases (93%) improved, and 4 cases (7%) died.There were 36 cases in the group with underlying diseases and 23 cases in the group without underlying diseases. No statistically significant differences were observed between the two groups in terms of length of hospital stay, ICU admission rate and length of ICU stay, mechanical ventilation rate, or mortality rate (all P>0.05). Conclusions: Non-HIV-infected children with PJP tend to occur in infants under 3 years old. It is often complicated by underlying diseases such as immunodeficiency, with most patients having a history of glucocorticoid or immunosuppressant use. Clinical manifestations and imaging findings lack specificity, and mNGS facilitates early diagnosis. The core treatment is trimethoprim-sulfamethoxazole, most children require respiratory support, and combination with low-dose glucocorticoids may improve prognosis. 目的: 探讨非人类免疫缺陷病毒(HIV)感染儿童肺孢子菌肺炎(PJP)的临床特征。 方法: 病例系列研究,分析四川大学华西第二医院儿科2022年2月至2025年6月收治的59例非HIV感染PJP患儿的一般资料、实验室指标、影像学特点、治疗和转归。根据是否合并基础疾病分为有基础疾病和无基础疾病组,组间比较采用Mann-Whitney U检验、χ2检验或Fisher确切概率法。 结果: 59例PJP患儿中,男40例、女19例,就诊年龄0.5(0.3,2.5)岁。59例PJP患儿中原发性免疫缺陷病12例(20%),自身免疫性疾病、血液肿瘤及器官移植各4例(11%);30例(51%)患儿诊断前有接受过糖皮质激素及免疫抑制剂治疗。59例PJP患儿表现为咳嗽57例(97%)、呼吸困难51例(86%)及发热35例(59%),59例PJP患儿外周血白细胞计数9.2(6.3,13.9)×109/L,中性粒细胞计数4.4(1.8,7.4)×109/L,淋巴细胞计数3.4(2.0,6.1)×109/L,C反应蛋白1.4(0.5,11.6)mg/L,降钙素原0.2(0.1,0.6)μg/L,乳酸脱氢酶(582±49)U/L。53%(16/30)患儿真菌G试验阳性;27%(11/41)患儿CD4+T细胞数<0.5×109/L,32%(13/41)患儿CD4+/CD8+<1.0。59例PJP患儿中影像学表现双肺多发实变影或片状影48例(81%)、弥漫性磨玻璃影29例(49%)及透光性降低20例(34%)。所有患儿均行病原体宏基因组二代测序发现肺孢子菌,57例(97%)患儿存在混合感染。59例患儿中采用复方磺胺甲噁唑单药治疗34例(58%),联用米卡芬净治疗19例(32%),联用克林霉素治疗7例(12%);53例(90%)患儿需要不同程度的呼吸支持,41例(70%)开始针对性治疗时予以糖皮质激素,55例(93%)好转,4例(7%)死亡。基础疾病组36例,无基础疾病组23例,两组患儿住院时间、重症监护病房入住率及入住时间、机械通气率、病死率差异均无统计学意义(均P>0.05)。 结论: 非HIV感染儿童PJP好发于3岁以下婴幼儿,常合并免疫缺陷等基础疾病,多有激素、免疫抑制剂使用史,临床表现和影像学缺乏特异性,宏基因组二代测序有助于早期诊断。治疗以复方磺胺甲噁唑为核心,多需呼吸支持,联用小剂量糖皮质激素可能改善预后。.
引用
- Chen D, Luo LL, Yang M, et al. [Clinical characteristics of Pneumocystis jirovecii pneumonia in non-human immunodeficiency virus infected children]. Zhonghua Er Ke Za Zhi. 2026. PMID: 41539958. doi:10.3760/cma.j.cn112140-20250811-00740
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。